Stephen Hall, MD
Psychiatry · San Francisco, CANPI 1447298625
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Acadia Pharmaceuticals Inc accounts for 98.3% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $18,111 and has fallen 99.5% since, to $98 in 2025. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 65 payments — averaging $546.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$35K
- Neurocrine Biosciences, Inc.$267
- Otsuka America Pharmaceutical, Inc.$148
- Axsome Therapeutics, Inc.$69
- Takeda Pharmaceuticals U.S.A., Inc.$61
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$47
- plus $18 from 1 others
What the payments were for
- Consulting fees$12,00034%
- Speaking & faculty fees$19,25054%
- Travel & lodging$2,5557%
- Food & beverage$1,6895%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acadia Pharmaceuticals Inc | 51 | $34,930 |
| Neurocrine Biosciences, Inc. | 6 | $267 |
| Otsuka America Pharmaceutical, Inc. | 2 | $148 |
| Axsome Therapeutics, Inc. | 2 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $61 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $47 |
| Alkermes, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,541 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 16 | $1,917 |
| Divalproex Sodium | 61 | $1,099 |
| Escitalopram Oxalate | 72 | $1,058 |
| Mirtazapine | 47 | $868 |
| Duloxetine Hcl | 42 | $836 |
| Clonazepam | 23 | $798 |
| Quetiapine Fumarate | 46 | $630 |
| Fluoxetine Hcl | 12 | $475 |
| Trazodone Hcl | 50 | $372 |
| Omega-3 Acid Ethyl Esters | 12 | $358 |
| Risperidone | 24 | $346 |
| Donepezil Hcl | 29 | $307 |
| Gabapentin | 44 | $302 |
| Nortriptyline Hcl | 13 | $197 |
| Bupropion Hcl SrBupropion Hcl | 11 | $96 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in San Francisco
- John KooSan Francisco$3M
- Thomas LewisSan Francisco$135K
- Gustavo AlvaOrange$5.8M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.